Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
On Thursday, Ligand Pharmaceuticals (NASDAQ: LGND ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. The full earnings call is available at Summary Full Transcri
Johnson & Johnson (NYSE:JNJ) is integrating its $14.6B Intra-Cellular Therapies buy while weighing Caplyta's expanded label after positive trials, reporting strong Carvykti long-term remission and survival data, completing a second pivotal Caplyta Phase 3 study, and announcing Tremfya success in ax…
Janssen's Tremfya receives FDA approval for joint damage inhibition, potentially expanding treatment options. This may impact JNJ stock.